Search Results for "Nuedexta"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Nuedexta. Results 1 to 3 of 3 total matches.
See also: dextromethorphan, quinidine
Dextromethorphan/Bupropion (Auvelity) for Depression
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022 (Issue 1666)
suppressant; it is also FDA-approved
in a fixed-dose combination with quinidine
(Nuedexta) for treatment ...
The FDA has approved an extended-release fixed-dose
combination of dextromethorphan and
bupropion (Auvelity – Axsome) for treatment of major
depressive disorder (MDD) in adults.
Brexpiprazole (Rexulti) for Agitation in Alzheimer's Dementia
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
(Nuedexta),
which is approved for treatment of pseudobulbar
affect, and dextromethorphan/bupropion ...
The FDA has approved the oral second-generation
antipsychotic drug brexpiprazole (Rexulti – Otsuka/Lundbeck) for once-daily treatment of agitation associated
with dementia due to Alzheimer's disease (AD).
Brexpiprazole is the first drug to be approved in the US
for this indication. It is also approved for treatment of
schizophrenia and as an adjunct to antidepressants for
treatment of major depressive disorder.
Med Lett Drugs Ther. 2023 Jun 26;65(1679):99-101 doi:10.58347/tml.2023.1679b | Show Introduction Hide Introduction
Drugs for Dementia
The Medical Letter on Drugs and Therapeutics • Mar 30, 2026 (Issue 1751)
antagonist and a sigma-1 receptor
agonist, and quinidine (Nuedexta) is FDA-approved
for treatment ...
Alzheimer's disease (AD) is the most common cause
of dementia, but cognitive decline also occurs in
other neurological conditions, such as Parkinson's
disease, Lewy body dementia, vascular dementia, and
frontotemporal dementia.
Med Lett Drugs Ther. 2026 Mar 30;68(1751):49-56 doi:10.58347/tml.2026.1751a | Show Introduction Hide Introduction